← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Acumen Pharmaceuticals, Inc.
South San Francisco, CA
$3,388,252
Total funding
5
Grants
Funding over time
peak $2.5M · FY2005–20$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,388,252 · 5
By mechanism
U01$2,836,536 · 2
R43$329,524 · 2
R41$222,192 · 1
Investigators at Acumen Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$1,256,516
U01 · FY2018 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$1,256,516
U01 · FY2018 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$1,135,517
U01 · FY2019 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$1,135,517
U01 · FY2019 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$797,087
U01 · FY2020 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild Alzheimer Disease$444,503
U01 · FY2017 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$354,369
U01 · FY2017 · AG
Supplemental Grant Request to existing 5U01AG053247 - 03 - TK/PK Assay Analysis and Development$262,500
U01 · FY2020 · AG
Development of a non-fibrillic amyloid-beta oligomer selective positron emission tomography imaging diagnostic for Alzheimer.$222,192
R41 · FY2016 · AG
Drug discovery of anti-ADDL therapeutics for Alzheimer's$183,750
R43 · FY2005 · AG
Biomarker for Alzheimer's Related Cognitive Deficits$145,774
R43 · FY2005 · AG
Amyloid-Beta Oligomer Selective Immunotherapy for Prodromal or Mild$90,134
U01 · FY2017 · AG